Dr. David Sallman, MD

• Hematology & Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of South Florida

  Medical School

• Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS), 2022-11-15

• PP2A: The Achilles Heal in MDS with 5q Deletion, 2014-09-23

• TP53-mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions, 2022-11-02

• S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes, 2019-02-08

• Examining disparities in large-scale patient-reported data capture using digital tools among cancer patients at clinical intake, 2023-08-18

• Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types, 2017-11-12

• Genomic characteristics and prognostic significance of co-mutatedASXL1/SRSF2acute myeloid leukemia, 2021-02-15

• Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype, 2016-06-16

• Prognostic Significance of MYC Oncoprotein Expression on Survival Outcome in Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC), 2019-07-18

• Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia, 2021-07-12

• Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML), 2020-07-29

• A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS), 2019-03-30

• ASXL1frameshift mutations drive inferior outcomes in CMML without negative impact in MDS, 2017-11-27

• Induction of Clusterin by AKT-Role in Cytoprotection against Docetaxel in Prostate Tumor Cells, 2010-05-25

• Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes, 2022-08-08

• Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction, 2022-09-01

• Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia, 2021-09-18

• Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutatedRUNX1versus acute myeloid leukemia with myelodysplasia-related changes with mutatedRUNX1, 2020-02-24

• Integrative molecular subtypes of acute myeloid leukemia, 2023-05-08

• TP53andMDM2single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes, 2015-09-25

• Impact of high molecular risk mutations on transplant outcomes in patients with myelofibrosis, 2019-01-06

• Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning, 2022-05-25

• Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome, 2022-11-04

• Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia, 2019-10-21

• MYC Overexpression is Associated with an Early Disease Progression from MDS to AML, 2021-10-21